Multiple myeloma and plasma cell dyscrasias
Management: PD Dr. Annamaria Brioli
Multiple myeloma - MM - is a malignant blood cancer and the second most common hematologic disease. However, thanks to numerous advances in recent years, the prognosis of myeloma patients has improved significantly. In addition to MM, other plasma cell dyscrasias such as AL amyloidosis are also of clinical importance. In our specialist consultation, we offer second opinions and advice as well as access to the latest therapies such as T-cell therapies and treatments in clinical trials. We work closely with the Amyloidosis Center and the Centre for Rare Diseases.
Clinical portfolio
- Second opinions for initial diagnosis and during the course of the disease
- Consultation for new adjustments or changes to MM medication
- MM diagnostics (clinical diagnostics, cytology, cytogenetic diagnostics)
- Advice on indication and implementation of CAR-T cell therapy
- Advice on clinical studies and newly approved drugs
- Rare plasma cell diseases (e.g. AL amyloidosis, POEMS syndrome in cooperation with the Amyloidosis Center and the Centre for Rare Diseases) and monoclonal gammopathies of clinical significance
Consultation hours and contact
MM specialty consultation
PD Dr. A. Brioli / Dr. K. Brinkert
MM coagulation consultation
Prof. Dr. A. Tiede / Dr. C. Dobbelstein
MM-CAR-T consultation
PD Dr. A. Brioli / PD Dr. C. Schultze-Florey
Registrations:
Information on participation in ongoing clinical trials can be found here.
Cooperations
- German Multiple Myeloma Study Group (DSMM)
- German-Speaking Myeloma Multiple Group (GMMG)
- European Myeloma Network (EMN)
- International Myeloma Society (IMS)
Promotes research, education, clinical trials (including diagnosis and treatment), workshops, conferences and symposia on all aspects of multiple myeloma worldwide. - German Society for Amyloid Diseases (DGAK)